The estimated Net Worth of D Keith Grossman is at least $15 Million dollars as of 3 June 2024. Mr. Grossman owns over 69,303 units of Nevro Corp stock worth over $404,693 and over the last 21 years he sold NVRO stock worth over $715,648. In addition, he makes $13,877,700 as Chairman of the Board, President, and Chief Executive Officer at Nevro Corp.
D has made over 16 trades of the Nevro Corp stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 69,303 units of NVRO stock worth $76,926 on 3 June 2024.
The largest trade he's ever made was exercising 69,303 units of Nevro Corp stock on 3 June 2024 worth over $76,926. On average, D trades about 1,155 units every 63 days since 2003. As of 3 June 2024 he still owns at least 85,922 units of Nevro Corp stock.
You can see the complete history of Mr. Grossman stock trades at the bottom of the page.
D.Keith Grossman is Chairman of the Board, President, Chief Executive Officer of the company. Mr. Grossman has over 30 years of experience in the medical device field. Mr. Grossman served most recently, and for the second time, as the President, Chief Executive Officer and director of Thoratec Corporation (“Thoratec”), leading up to its 2015 sale to St. Jude Medical. Prior to Thoratec, he served as President, Chief Executive Officer and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Mr. Grossman served as managing director of Texas Pacific Group (“TPG”), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, Chief Executive Officer and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as Chairman of the Board of Outset Medical, Inc., a privately-held company, as Vice Chairman of Alcon, Inc., as a board member of ViewRay, Inc. and previously served as a member of the board of directors of Intuitive Surgical, Inc., Kyphon, Inc., Zeltiq and a number of privately-held medical device companies. Mr. Grossman received a B.S. in Animal Science from The Ohio State University and an M.B.A. from Pepperdine University.
As the Chairman of the Board, President, and Chief Executive Officer of Nevro Corp, the total compensation of D Grossman at Nevro Corp is $13,877,700. There are no executives at Nevro Corp getting paid more.
D Grossman is 59, he's been the Chairman of the Board, President, and Chief Executive Officer of Nevro Corp since 2019. There are 14 older and 10 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
D's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo, and & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
Nevro Corp executives and other stock owners filed with the SEC include: